Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL006 combination therapy in advanced solid tumors
NCT07157956Phase 2Not yet recruiting
- Sponsor
- Convalife Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Aug 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CVL006 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), malignant pleural mesothelioma (MPM), triple-negative breast cancer (TNBC), breast cancer, sponsored by Convalife Pharmaceutical. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
CVL006
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)malignant pleural mesothelioma (MPM)triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on NCT07157956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07157956.